Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-01-31
DOI
10.1186/s12933-023-01752-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
- (2023) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment
- (2022) David Kallend et al. Journal of Clinical Lipidology
- Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia
- (2022) M Doortje Reijman et al. European Journal of Preventive Cardiology
- Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
- (2022) Nihar R. Desai et al. American Journal of Cardiovascular Drugs
- Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
- (2022) Essie Samuel et al. ANNALS OF PHARMACOTHERAPY
- PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
- (2022) Xing Wang et al. Cardiovascular Diabetology
- Considerations and recommendations for assessment of plasma protein binding and drug–drug interactions for siRNA therapeutics
- (2022) Sara C Humphreys et al. NUCLEIC ACIDS RESEARCH
- An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study
- (2022) David Kallend et al. CTS-Clinical and Translational Science
- 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2022) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
- (2022) Christina Reith et al. LANCET
- Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol
- (2022) Peter P. Toth et al. Journal of the American Heart Association
- Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
- (2022) Maciej Banach et al. Cardiovascular Diabetology
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
- (2021) Emily Herrett et al. BMJ-British Medical Journal
- The Nonclinical Disposition and PK/PD Properties of GalNAc-conjugated siRNA Are Highly Predictable and Build Confidence in Translation to Man
- (2021) Robin McDougall et al. DRUG METABOLISM AND DISPOSITION
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- (2021) Frank L J Visseren et al. EUROPEAN HEART JOURNAL
- Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
- (2021) Bhavani Shankara Bagepally et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- (2020) Jan Borén et al. EUROPEAN HEART JOURNAL
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia
- (2020) G. Kees Hovingh et al. CIRCULATION
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry)
- (2019) Angela Lowenstern et al. AMERICAN JOURNAL OF CARDIOLOGY
- Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry
- (2019) Corey K. Bradley et al. Journal of the American Heart Association
- Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
- (2019) Guy De Backer et al. ATHEROSCLEROSIS
- Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
- (2019) Paul Guedeney et al. EUROPEAN HEART JOURNAL
- The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice
- (2019) Corey K. Bradley et al. Journal of Clinical Lipidology
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk
- (2018) Vicki Fung et al. PLoS One
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab
- (2018) Arman Qamar et al. JAMA Cardiology
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years
- (2017) Michel Farnier et al. Journal of Clinical Lipidology
- Structural Foundations of RNA Silencing by Argonaute
- (2017) Jessica Sheu-Gruttadauria et al. JOURNAL OF MOLECULAR BIOLOGY
- Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction
- (2017) Maria-Corina Serban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
- (2017) Erin A. Bohula et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Inhibitors
- (2017) Mark A. Hlatky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
- (2017) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents
- (2016) Paul M Ridker et al. EUROPEAN HEART JOURNAL
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients
- (2015) Olivier Descamps et al. ATHEROSCLEROSIS
- Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes
- (2015) Sripal Bangalore et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
- (2014) Jayaprakash K. Nair et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
- (2014) S. Matthijs Boekholdt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol
- (2011) Judith Hsia et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Medication Adherence: WHO Cares?
- (2011) Marie T. Brown et al. MAYO CLINIC PROCEEDINGS
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The LDL Receptor
- (2009) Joseph L. Goldstein et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started